Integrating the Latest Evidence Into KRAS Molecular Testing for NSCLC

Integrating the Latest Evidence Into KRAS Molecular Testing for NSCLC

Registration for this event has closed.

Partner Image

Live Webinar Snapshot

Activity Type:
Live Webinar
Duration:
30 minutes
Activity Price:
Free
Broadcast Date:
  • Tuesday, Sep 28, 2021 at 2:00 PM Eastern (11:00 AM Pacific)
Continuing Education Credits:

Faculty

▸ Tue, Sep 28

Gilberto de Lima Lopes, Jr, MD, MBA, FAMS

Course Director and Speaker
Gilberto de Lima Lopes, Jr, MD, MBA, FAMS

Professor of Clinical Medicine
Medical Director, International Programs
Associate Director, Global Oncology
Interim Chief, Division of Medical Oncology
University of Miami Sylvester Comprehensive Cancer Center
Miami, FL

Soo-Ryum Yang, MD

Speaker
Soo-Ryum Yang, MD

Assistant Attending Pathologist
Memorial Sloan Kettering Cancer Center
New York, NY

Douglas S Burgoyne, PharmD, FAMCP

Moderator
Douglas S Burgoyne, PharmD, FAMCP

Adjunct Associate Professor
Department of Pharmacotherapy
University of Utah College of Pharmacy
Salt Lake City, UT

Mark A Rubin, MD

Planner

Medical Director
Humana
Fort Lauderdale, FL

Ryan M Burke, PharmD

Planner

Director, Professional Affairs
Pharmacy Technician Certification Board
Washington, DC

Judith R Sands, RN, MSL, BSN, CCM, CPHQ, CPHRM, ARM

Peer Reviewer

Clinical Consultant and Author
Raleigh, NC

Agenda

  1. Practice Insights: Lessons From a New Survey in NSCLC
  2. Implications of KRAS Mutations for Patient Prognosis and NSCLC Treatment Planning
  3. Expert Strategies to Overcome Challenges in NSCLC Biomarker Testing
  4. Case Discussion: Who, When, and How to Appropriately Test for KRAS Mutations

Learning Objectives

  • Assess best practices for KRAS biomarker testing in non-small cell lung cancer (NSCLC)
  • Develop evidence-based, biomarker-directed treatment plans for patients with NSCLC

Intended Audience: physicians, PAs, NPs, pharmacists, nurses specializing in oncology

The availability of KRAS G12C-targeted agents opens up new opportunities for biomarker-driven care, affecting about as many non-small cell lung cancer (NSCLC) patients as those with EGFR-driven tumors. How should molecular diagnostics be applied to optimal identification of these patients so they can receive evidence-based care? Get expert advice on who, how, and when to test for KRAS G12C, including tips for overcoming barriers to appropriate molecular testing in all patients with NSCLC.

Accreditation Information

Joint Accreditation Statement

IPCE Credit™In support of improving patient care, PRIME® is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Credit Designation Statement

ACCME Logo

PRIME® designates this Live activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

MOC Points

ACCME MOC LogoSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Physician Assistant Accreditation Statement

AAPA Logo

PRIME® has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

Nurse Practitioner Accreditation Statement

Nurse Practitioner LogoPRIME Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 060815. This activity is approved for 0.5 contact hour (which includes 0.5 hour of pharmacology).

Pharmacist Accreditation Statement

ACPE Logo

This Application-based activity has been approved for 0.5 contact hour (0 CEUs) by PRIME® for pharmacists. The Universal Activity Number for this activity is JA0007144-0000-21-150-L01-P . Pharmacy CE credits can be submitted to the NABP upon successful completion of the activity by providing your NABP ID & DOB, which must be submitted within 60 days of completion. Pharmacists with questions can contact NABP customer service (help@nabp.pharmacy).

Nurse Accreditation Statement

ANCC Logo

PRIME® designates this activity for 0.5 contact hour.

Obtaining CE Credit

  1. Register using the online form
  2. Complete the pre-registration survey
  3. Attend the live program in its entirety
  4. Complete an online evaluation and post-test
  5. Download and/or print a certificate of completion and/or submit CE credits electronically

Instructions to access CME/CE credit options will be provided at the end of the program.

Method of Participation

This live CME/CE activity requires attendance of the participant during the entire program and completion of learner assessment tools. The learner will then receive instructions on how to download and/or print a certificate of completion and/or submit CE credits electronically.

Device Requirements

  • Hardware: an Internet-enabled computer, smartphone, tablet, or mobile device with audio capabilities and Internet connectivity
  • Software: the installation of software such as GoToWebinar may be required

*PRIME® has identified, reviewed, and mitigated all relevant financial relationships that speakers, authors, course directors, planners, peer reviewers, or relevant staff disclose prior to the delivery of any educational activity.

The following individuals have identified relevant financial relationships with ineligible companies to disclose:

  • Gilberto de Lima Lopes, Jr, MD, MBA, FAMS (Course Director, Speaker)
    ConsultantAstraZeneca, Pfizer
    Grants / Research SupportAbbVie, Adaptimmune, AstraZeneca, Bavarian Nordic, Blueprint Medicines, Bristol-Myers Squibb, EMD Serono, ER Squibb Sons LLC, G1 Therapeutics, GlaxoSmithKline, Janssen, Lilly, Lucence, Merck Sharp & Dohme, Novartis, Pfizer, Rgenix, Roche, Tesaro, Xilis
    Other Financial or Material Support (royalties, patents, etc.)Boehringer Ingelheim, Celgene, ER Squibb Sons LLC, Janssen, Pfizer, Seagen (Seattle Genetics)
    The relationships reported above are related to the following therapeutic area: Oncology
  • Soo-Ryum Yang, MD (Speaker)
    ConsultantInvitae

The following individuals have no relevant financial relationships with ineligible companies to disclose:

  • Douglas S Burgoyne, PharmD, FAMCP (Moderator)
  • Judith R Sands, RN, MSL, BSN, CCM, CPHQ, CPHRM, ARM (Reviewer)
  • Mark A Rubin, MD (Planner)
  • Ryan M Burke, PharmD (Planner)

All PRIME® staff participating in planning and content development have no relevant financial relationships with ineligible companies to disclose.

Resource Center

This activity is also part of a Resource Center. If you're interested in learning more about this topic, we strongly advise you to visit one of our Resource Centers listed below. Resource Centers are a selected collection of activities all connected to the same theme.

Funding Disclosure

This activity is provided by PRIME Education. There is no fee to participate. This activity is supported by educational funding provided by Amgen.

Accessibility Statement

At PRIME, we are committed to ensuring that individuals with disabilities can access all of the content offered by PRIME through our website and other properties. If you are having trouble accessing primeinc.org, please email legal@ziffdavis.com for assistance. Please put "ADA Inquiry" in the subject line of your email.